CAR T beats bispecific drugs at keeping lymphoma away, study finds
A study of 228 patients with relapsed follicular lymphoma compared CAR T-cell therapy with bispecific antibodies. CAR T kept the disease away longer and led to more complete responses. But patients spent more days in hospital in the first month and had more serious side effects. Overall survival was the same.
Where this came from. 2 outlets reported this. We read them, then wrote the sixty words above.